Skip to main content
Premium Trial:

Request an Annual Quote

Axela, Cronus Ink Distribution Deal for UK, Ireland

NEW YORK (GenomeWeb News) – Cronus Technologies and Axela today announced a distribution deal to market Axela's instruments in the UK and Ireland.

Cronus will manage the sales and support of Axela's flow-through systems in both countries under the terms of the deal. The systems include the fully automated Ziplex Research System for gene and protein microarray analysis, and the dotLab mX System for real-time, multiplex immunoassays. Cronus will also market Axela's panelPlus Technology for creating custom multiplex panels for flow-through biomarker analysis.

"The Ziplex and dotLab mX product range adds another string to our biomarker discovery and validation portfolio and allows us to truly collaborate with our customers in a meaningful and strategic way," Kevin Fairman, CEO of Cronus, said in a statement. "This positive addition combined with a great working relationship with the Axela team will allow our customers to push the boundaries and time constraints in biomarker research."

The companies did not reveal the terms of the deal, which follows an agreement Toronto-based Axela inked with Digilab in August to distribute Axela's products in the US.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.